Possible biomarkers modulating haloperidol efficacy and/or tolerability

Pharmacogenomics. 2016 Apr;17(5):507-29. doi: 10.2217/pgs.16.5. Epub 2016 Mar 29.

Abstract

Haloperidol (HP) is widely used in the treatment of several forms of psychosis. Despite of its efficacy, HP use is a cause of concern for the elevated risk of adverse drug reactions. adverse drug reactions risk and HP efficacy greatly vary across subjects, indicating the involvement of several factors in HP mechanism of action. The use of biomarkers that could monitor or even predict HP treatment impact would be of extreme importance. We reviewed the elements that could potentially be used as peripheral biomarkers of HP effectiveness. Although a validated biomarker still does not exist, we underlined the several potential findings (e.g., about cytokines, HP metabolites and genotypic biomarkers) which could pave the way for future research on HP biomarkers.

Keywords: cytokines; genetics; haloperidol; metabolites; peripheral biomarkers.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use*
  • Biomarkers / analysis
  • Epigenesis, Genetic
  • Gene Expression Profiling
  • Genetic Markers
  • Genotype
  • Haloperidol / adverse effects
  • Haloperidol / pharmacology
  • Haloperidol / therapeutic use*
  • Humans
  • Organ Specificity
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / genetics

Substances

  • Antipsychotic Agents
  • Biomarkers
  • Genetic Markers
  • Haloperidol